Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Afatinib + ONO-7475 + Verteporfin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Afatinib | Gilotrif | BIBW 2992|Giotrif | EGFR Inhibitor (Pan) 62 EGFR Inhibitor 2nd gen 5 HER inhibitor (Pan) 6 | Gilotrif (afatinib) is a second-generation pan-Egfr inhibitor with activity against EGFR T790M and EGFR exon 19 and 21 deletions, and also inhibits ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4) (PMID: 24435321, PMID: 25505694). Gilotrif (afatinib) is FDA approved for use in non-small cell lung cancer patients harboring non-resistant EGFR mutations, including exon 19 deletions, L858R, S768I, G719X, and L861Q, and for patients with metastatic squamous NSCLC (FDA.gov). |
ONO-7475 | ONO7475 | AXL Inhibitor 30 FLT3 Inhibitor 69 MERTK Inhibitor 13 TYRO3 Inhibitor 8 | ONO-7475 inhibits AXL, MERTK, FLT3, and TYRO3, potentially leading to reduced growth and increased apoptosis of tumor cells (PMID: 28912176, PMID: 30501104, PMID: 31953310). | |
Verteporfin | Visudyne | YAP Inhibitor 3 | Visudyne (verteporfin) is a small molecule that binds to YAP1 and inhibits the interaction between YAP1 and TEAD, potentially resulting in decreased growth of YAP-driven tumor cells (PMID: 22677547, PMID: 28576749). Verteporfin is FDA-approved for treatment of age-related macular degeneration (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|